{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:19:15Z","timestamp":1788315555930,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40256-026-00792-x","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:19:29Z","timestamp":1774009169000},"page":"419-433","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Transplant Recipients: A Systematic Review and Meta-analyses"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1228-1941","authenticated-orcid":false,"given":"Nelson Luis","family":"Cahuapaza-Gutierrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5242-3141","authenticated-orcid":false,"given":"Cielo Cinthya","family":"Calderon-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5700-9052","authenticated-orcid":false,"given":"Mariam Miyanay","family":"Umeres-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0497-7042","authenticated-orcid":false,"given":"Tatiana Vanessa","family":"Villavicencio-Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"issue":"7","key":"792_CR1","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jchf.2020.01.014","volume":"8","author":"LK Truby","year":"2020","unstructured":"Truby LK, Rogers JG. Advanced heart failure: epidemiology, diagnosis, and therapeutic approaches. JACC Heart Fail. 2020;8(7):523\u201336.","journal-title":"JACC Heart Fail"},{"issue":"1","key":"792_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1053\/j.jvca.2022.09.083","volume":"37","author":"NC Hwang","year":"2023","unstructured":"Hwang NC, Sivathasan C. Review of postoperative care for heart transplant recipients. J Cardiothorac Vasc Anesth. 2023;37(1):112\u201326.","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"4","key":"792_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.healun.2024.12.006","volume":"44","author":"A Gorrai","year":"2025","unstructured":"Gorrai A, Farr M, O\u2019hara P, Beaini H, Hendren N, Wrobel C, et al. Novel therapeutic agents for cardiometabolic risk mitigation in heart transplant recipients. J Heart Lung Transplant. 2025;44(4):477\u201386.","journal-title":"J Heart Lung Transplant"},{"issue":"10","key":"792_CR4","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.healun.2016.08.017","volume":"35","author":"LH Lund","year":"2016","unstructured":"Lund LH, Edwards LB, Dipchand AI, Goldfarb S, Kucheryavaya AY, Levvey BJ, et al. The Registry of the International Society for Heart and Lung Transplantation: thirty-third adult heart transplantation report\u20142016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant. 2016;35(10):1158\u201369.","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"792_CR5","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/joim.20077","volume":"297","author":"FS Yen","year":"2025","unstructured":"Yen FS, Hung YM, Huang JY, Hsu CC, Cheng WY, Hwu CM, et al. Effects of SGLT2 inhibitors on transplant survival and key clinical outcomes in heart transplant recipients with diabetes. J Intern Med. 2025;297(5):532\u201342.","journal-title":"J Intern Med"},{"issue":"9","key":"792_CR6","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1111\/ajt.12850","volume":"14","author":"A Sharif","year":"2014","unstructured":"Sharif A, Hecking M, de Vries APJ, Porrini E, Hornum M, Rasoul-Rockenschaub S, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014;14(9):1992\u20132000.","journal-title":"Am J Transplant"},{"issue":"1","key":"792_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15441","volume":"42","author":"CA Muir","year":"2025","unstructured":"Muir CA, Kuang W, Muthiah K, Greenfield JR, Raven LM. Association of early post-transplant hyperglycaemia and diabetes mellitus on outcomes following heart transplantation. Diabet Med. 2025;42(1):e15441.","journal-title":"Diabet Med"},{"issue":"12","key":"792_CR8","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761\u201372.","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"792_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.36628\/ijhf.2022.0030","volume":"5","author":"KM Talha","year":"2023","unstructured":"Talha KM, Anker SD, Butler J. SGLT-2 inhibitors in heart failure: a review of current evidence. Int J Heart Fail. 2023;5(2):82\u201390.","journal-title":"Int J Heart Fail"},{"key":"792_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01816-5","volume":"22","author":"K Huang","year":"2023","unstructured":"Huang K, Luo X, Liao B, Li G, Feng J. Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms. Cardiovasc Diabetol. 2023;22:86.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"792_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000000885","volume":"5","author":"MG Cehic","year":"2019","unstructured":"Cehic MG, Muir CA, Greenfield JR, Hayward C, Jabbour A, Keogh A, et al. Efficacy and safety of empagliflozin in the management of diabetes mellitus in heart transplant recipients. Transplant Direct. 2019;5(5):e450.","journal-title":"Transplant Direct"},{"issue":"1","key":"792_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.","journal-title":"Syst Rev"},{"key":"792_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"792_CR14","doi-asserted-by":"crossref","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane handbook for systematic reviews of interventions. Cochrane Handb Syst Rev Interv. 2019;10(10):ED000142.","DOI":"10.1002\/9781119536604"},{"key":"792_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-45","volume":"14","author":"CKL Lo","year":"2014","unstructured":"Lo CKL, Mertz D, Loeb M. Newcastle\u2013Ottawa scale: comparing reviewers\u2019 to authors\u2019 assessments. BMC Med Res Methodol. 2014;14:45.","journal-title":"BMC Med Res Methodol"},{"key":"792_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"792_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"issue":"8","key":"792_CR18","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.healun.2017.05.005","volume":"36","author":"CA Muir","year":"2017","unstructured":"Muir CA, Greenfield JR, MacDonald PS. Empagliflozin in the management of diabetes mellitus after cardiac transplantationResearch Correspondenceretain-->. J Heart Lung Transplant. 2017;36(8):914\u20136.","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"792_CR19","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.healun.2021.02.012","volume":"40","author":"Y Sammour","year":"2021","unstructured":"Sammour Y, Nassif M, Magwire M, Thomas M, Fendler T, Khumri T, et al. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: initial report from a cardiometabolic center of excellence. J Heart Lung Transplant. 2021;40(6):426\u20139.","journal-title":"J Heart Lung Transplant"},{"key":"792_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhlto.2024.100088","volume":"5","author":"LM Raven","year":"2024","unstructured":"Raven LM, Muir CA, Deveza RC, Kessler Iglesias C, Bart NK, Muthiah K, et al. Effect of sodium glucose cotransporter 2 inhibition immediately prior to heart transplantation. JHLT Open. 2024;5:100088.","journal-title":"JHLT Open"},{"issue":"2","key":"792_CR21","first-page":"242","volume":"41","author":"YM Lu","year":"2025","unstructured":"Lu YM, Chang CY, Chen MF, Lu KH, Chang CY, Wei J, et al. Are there any renoprotective effects of sglt2 inhibitors in heart transplant recipients with diabetes? Acta Cardiol Sin. 2025;41(2):242\u201350.","journal-title":"Acta Cardiol Sin."},{"key":"792_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhlto.2025.100255","volume":"8","author":"LM Raven","year":"2025","unstructured":"Raven LM, Greenfield JR, Jabbour A, Macdonald PS, Muir CA. Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation. JHLT Open. 2025;8:100255.","journal-title":"JHLT Open"},{"issue":"8","key":"792_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.102520","volume":"13","author":"L Brinker","year":"2025","unstructured":"Brinker L, Sideris K, Wei G, Singh R, Nevers MR, Hartsell SE, et al. Diabetes therapy with SGLT2i after heart transplant: a multi-institutional analysis. JACC Heart Fail. 2025;13(8):102520.","journal-title":"JACC Heart Fail."},{"key":"792_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.777861","volume":"8","author":"JI Fonseca-Correa","year":"2021","unstructured":"Fonseca-Correa JI, Correa-Rotter R. Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review. Front Med. 2021;8:777861.","journal-title":"Front Med"},{"issue":"5","key":"792_CR25","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cardfail.2022.02.010","volume":"28","author":"Writing Committee Members","year":"2022","unstructured":"Writing Committee Members, ACC\/AHA Joint Committee Members. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure. J Card Fail. 2022;28(5):e1-167.","journal-title":"J Card Fail"},{"issue":"Suppl 1","key":"792_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13300-022-01277-1","volume":"13","author":"M Botana","year":"2022","unstructured":"Botana M, Escalada J, Merchante \u00c1, Reyes R, Rozas P. Prevention of cardiorenal complications with sodium-glucose cotransporter type 2 inhibitors: a narrative review. Diabetes Ther. 2022;13(Suppl 1):5\u201317.","journal-title":"Diabetes Ther"},{"issue":"2","key":"792_CR27","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1536\/ihj.22-441","volume":"64","author":"S Ge","year":"2023","unstructured":"Ge S, Liu R, Mao Y, Geng C, Wang H, Song K, et al. Safety of SGLT2 inhibitors in three chronic diseases. Int Heart J. 2023;64(2):246\u201351.","journal-title":"Int Heart J"},{"key":"792_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-023-01092-z","volume":"15","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Zhou S, Liu L. Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis. Diabetol Metab Syndr. 2023;15:118.","journal-title":"Diabetol Metab Syndr"},{"issue":"2","key":"792_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2023.101419","volume":"49","author":"AJ Scheen","year":"2023","unstructured":"Scheen AJ, Bonnet F. Efficacy and safety profile of SGLT2 inhibitors in the elderly: how is the benefit\/risk balance? Diabetes Metab. 2023;49(2):101419.","journal-title":"Diabetes Metab"},{"issue":"19","key":"792_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910822","volume":"22","author":"A Winiarska","year":"2021","unstructured":"Winiarska A, Knysak M, Nabrdalik K, Gumprecht J, Stomp\u00f3r T. Inflammation and oxidative stress in diabetic kidney disease: the targets for SGLT2 inhibitors and GLP-1 receptor agonists. Int J Mol Sci. 2021;22(19):10822.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"792_CR31","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s13300-019-00686-z","volume":"10","author":"DK Patel","year":"2019","unstructured":"Patel DK, Strong J. The pleiotropic effects of sodium\u2013glucose cotransporter-2 inhibitors: beyond the glycemic benefit. Diabetes Ther. 2019;10(5):1771.","journal-title":"Diabetes Ther"},{"issue":"8","key":"792_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12082824","volume":"12","author":"A Rastogi","year":"2023","unstructured":"Rastogi A, James L, Januzzi J. Pleiotropic effects of sodium-glucose cotransporter-2 inhibitors in cardiovascular disease and chronic kidney disease. J Clin Med. 2023;12(8):2824.","journal-title":"J Clin Med"},{"key":"792_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2025.133083","volume":"426","author":"MZ Ameer","year":"2025","unstructured":"Ameer MZ, Rehman AU, Amjad Z, Khan S, Ameer F, Shirwany HAK, et al. Cardiovascular outcomes with SGLT-2 inhibitors in individuals with diabetes and co-existing atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol. 2025;426:133083.","journal-title":"Int J Cardiol"},{"issue":"8","key":"792_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102648","volume":"49","author":"A Idowu","year":"2024","unstructured":"Idowu A, Adebolu O, Wattanachayakul P, Obomanu E, Shah S, Lo KB, et al. Cardiovascular outcomes of sodium-glucose co-transporter 2 inhibitors use after myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol. 2024;49(8):102648.","journal-title":"Curr Probl Cardiol"},{"issue":"3","key":"792_CR35","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/14796678.2025.2464449","volume":"21","author":"U Khan","year":"2025","unstructured":"Khan U, Amin AM, Mohamed Taha A, Khlidj Y, M. AlBarakat M, Elewidi M, et al. The effect of sodium-glucose co-transporter 2 inhibitors on clinical outcomes after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Future Cardiol. 2025;21(3):177\u201390.","journal-title":"Future Cardiol"},{"issue":"6","key":"792_CR36","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/MNH.0000000000000749","volume":"30","author":"TG Jenssen","year":"2021","unstructured":"Jenssen TG. Efficacy and safety of sodium-glucose-transporter-2 inhibitors in kidney transplant patients. Curr Opin Nephrol Hypertens. 2021;30(6):577\u201383.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"792_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/MNH.0000000000000948","volume":"33","author":"G Mahalwar","year":"2024","unstructured":"Mahalwar G, Mathew RO, Rangaswami J. Sodium-glucose cotransporter 2 inhibitors and cardiorenal outcomes in kidney transplantation. Curr Opin Nephrol Hypertens. 2024;33(1):53.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"792_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108604","volume":"172","author":"D Oikonomaki","year":"2021","unstructured":"Oikonomaki D, Dounousi E, Duni A, Roumeliotis S, Liakopoulos V. Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2021;172:108604.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"792_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2022.100729","volume":"37","author":"Y Lin","year":"2023","unstructured":"Lin Y, Mok M, Harrison J, Battistella M, Farrell A, Leung M, et al. Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: a systematic review. Transplant Rev. 2023;37(1):100729.","journal-title":"Transplant Rev"},{"issue":"6","key":"792_CR40","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/phar.2928","volume":"44","author":"H Mreyoud","year":"2024","unstructured":"Mreyoud H, Walter K, Wilpula E, Park JM. The efficacy and safety of sodium-glucose cotransporter-2 inhibitors in solid organ transplant recipients: a scoping review. Pharmacotherapy. 2024;44(6):444\u201366.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"792_CR41","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10741-024-10465-z","volume":"30","author":"E Alyaydin","year":"2024","unstructured":"Alyaydin E, Parianos D, Hermes-Laufer J, N\u00e4gele MP, Castro L, Papathanasiou M, et al. Sodium-glucose co-transporter 2 inhibitors in left ventricular assist device and heart transplant recipients: a mini-review. Heart Fail Rev. 2024;30(2):327.","journal-title":"Heart Fail Rev"},{"issue":"1","key":"792_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.mcna.2016.08.011","volume":"101","author":"AL Bennett","year":"2017","unstructured":"Bennett AL, Ventura HO. Hypertension in patients with cardiac transplantation. Med Clin North Am. 2017;101(1):53\u201364.","journal-title":"Med Clin North Am"},{"issue":"9","key":"792_CR43","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.2217\/pgs.14.87","volume":"15","author":"AD Moes","year":"2014","unstructured":"Moes AD, Hesselink DA, Zietse R, van Schaik RHN, van Gelder T, Hoorn EJ. Calcineurin inhibitors and hypertension: a role for pharmacogenetics? Pharmacogenomics. 2014;15(9):1243\u201351.","journal-title":"Pharmacogenomics"},{"issue":"4","key":"792_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/hearts6040032","volume":"6","author":"ER Rashed","year":"2025","unstructured":"Rashed ER, Sundaravel S, Ortega-Legaspi JM. A review of systemic hypertension in the cardiac transplant population: pathophysiology, management, and future directions. Hearts. 2025;6(4):32.","journal-title":"Hearts."},{"issue":"11","key":"792_CR45","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/j.ajt.2025.08.013","volume":"25","author":"LM Raven","year":"2025","unstructured":"Raven LM, Brinker L, Sideris K, Muir CA, Carter S, Beddhu S, et al. Sodium glucose cotransporter 2 inhibitor use after heart transplant: current knowledge and potential applications. Am J Transplant. 2025;25(11):2303\u201312.","journal-title":"Am J Transplant"},{"issue":"4","key":"792_CR46","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/HCO.0000000000001145","volume":"39","author":"JD Torres","year":"2024","unstructured":"Torres JD, Krim SR. Management of hypertension in heart transplant recipients: an ongoing conundrum. Curr Opin Cardiol. 2024;39(4):273\u20138.","journal-title":"Curr Opin Cardiol"},{"issue":"1","key":"792_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01607-4","volume":"21","author":"L Leccisotti","year":"2022","unstructured":"Leccisotti L, Cinti F, Sorice GP, D\u2019Amario D, Lorusso M, Guzzardi MA, et al. Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART trial: a preliminary report. Cardiovasc Diabetol. 2022;21(1):173.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"792_CR48","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004007","volume":"6","author":"M Mazidi","year":"2017","unstructured":"Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium\u2010glucose cotransport\u20102 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta\u2010analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2017;6(6):e004007.","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis"},{"issue":"1","key":"792_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","volume":"35","author":"MR Mehra","year":"2016","unstructured":"Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 2016;35(1):1\u201323.","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"792_CR50","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"AF Members","year":"2022","unstructured":"Members AF, McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2022;24(1):4\u2013131.","journal-title":"Eur J Heart Fail"},{"key":"792_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/frtra.2024.1379695","volume":"3","author":"MF Holt","year":"2024","unstructured":"Holt MF, Holmen S, Rolid K, Englund KVB, \u00d8stby CM, Ravnestad H, et al. The association between body mass index, exercise capacity, and health-related quality of life in heart transplant recipients. Front Transplant. 2024;3:1379695.","journal-title":"Front Transplant"},{"issue":"23","key":"792_CR52","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021346","volume":"10","author":"F Chouairi","year":"2021","unstructured":"Chouairi F, Milner A, Sen S, Guha A, Stewart J, Jastreboff AM, et al. Impact of obesity on heart transplantation outcomes. J Am Heart Assoc. 2021;10(23):e021346.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"792_CR53","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1097\/MAT.0000000000001566","volume":"68","author":"K Miura","year":"2022","unstructured":"Miura K, Yu R, Sivapalan K, Liyanage UE, Entwistle T, McKenzie SC, et al. Weight gain after heart transplantation in adults: systematic review and meta-analysis. ASAIO J. 2022;68(9):1107.","journal-title":"ASAIO J"},{"issue":"5","key":"792_CR54","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032676","volume":"13","author":"L Holzhauser","year":"2024","unstructured":"Holzhauser L, Reza N, Edwards JJ, Birati EY, Owens AT, McLean R, et al. Emergency department use and hospital mortality among heart transplant recipients in the United States. J Am Heart Assoc. 2024;13(5):e032676.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"792_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030784","volume":"11","author":"G Spitaleri","year":"2022","unstructured":"Spitaleri G, Zamora E, Cediel G, Codina P, Santiago-Vacas E, Domingo M, et al. Cause of death in heart failure based on etiology: long-term cohort study of all-cause and cardiovascular mortality. J Clin Med. 2022;11(3):784.","journal-title":"J Clin Med"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00792-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-026-00792-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00792-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T13:03:14Z","timestamp":1781182994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-026-00792-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["792"],"URL":"https:\/\/doi.org\/10.1007\/s40256-026-00792-x","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nelson Luis Cahuapaza-Gutierrez:\u00a0writing\u2014original draft, visualization, validation, supervision, methodology, investigation, formal analysis, data curation, conceptualization. Cielo Cinthya Calderon-Hernandez:\u00a0writing\u2014review and editing, supervision, project administration, methodology, investigation, formal analysis. data curation, conceptualization. Mariam Miyanay Umeres-Bravo: writing\u2014review and editing, validation, investigation, conceptualization. Tatiana Vanessa Villavicencio-Escudero: writing\u2014review and editing, validation, investigation, data curation, conceptualization.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship contribution statement"}},{"value":"The present review study does not require ethical approval, because it is a study of synthesis and analysis of data from primary articles.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No new data were created for this review.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}